載入...
Daclizumab high-yield process in the treatment of relapsing–remitting multiple sclerosis
Daclizumab is a humanized monoclonal antibody that binds to the α subunit (CD25) of the interleukin-2 receptor and favorably modulates the immune environment in multiple sclerosis (MS). Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56(bright) natural k...
Na minha lista:
| 發表在: | Ther Adv Neurol Disord |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5400154/ https://ncbi.nlm.nih.gov/pubmed/28450896 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285616671887 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|